A Heartbeat Without Surgery: The Future of Temporary Light-Controlled Pacemakers

By Ananya Chopra,

The Lawrenceville School, NJ

Recent advancements in medical technology have led to the creation of a millimeter-scale, bioresorbable pacemaker capable of providing temporary cardiac pacing without invasive surgery (Lee et al., 2015). Unlike traditional temporary pacemakers, which rely on external wires and surgically implanted leads, this innovative device is optically powered, minimally invasive, and dissolves naturally within the body after use (Hwang et al., 2022). Its successful testing in animal and human heart models demonstrates significant potential not only for cardiac care but also for applications in nerve stimulation, bone healing, and pain management (Yu et al., 2020). This breakthrough represents a major shift in temporary medical implants, offering improved safety, reduced risk of infection, and greater patient comfort compared to conventional pacing systems.

Traditional temporary pacemakers operate by delivering electrical impulses to the heart via leads that are either inserted transvenously or attached directly to the cardiac surface during surgery (Kusumoto et al., 2019). These leads remain connected to an external pulse generator, requiring wires that exit the body, which increases the risk of infection, lead dislodgement, and restricted patient mobility. In contrast, the bioresorbable pacemaker eliminates these complications through a fully internalized, lead-free design (Lee et al., 2015). The device is powered by near-infrared light transmitted through the skin, which is converted into electrical energy to stimulate the heart. This optical control mechanism enables wireless operation, removing the need for external hardware. When paired with a wearable sensor, the pacemaker can autonomously detect arrhythmias and adjust pacing parameters in real time without manual intervention (Hwang et al., 2022).

The device is constructed from biocompatible materials such as magnesium, silicon, and poly lactic-co-glycolic acid (PLGA), which gradually dissolve in the body over a predetermined period (Yu et al., 2020). This ensures that the pacemaker does not require surgical extraction, thereby minimizing secondary complications. The dissolution process is carefully calibrated to maintain functionality throughout the required pacing duration, while ensuring complete resorption once the device is no longer needed. Traditional temporary pacing systems, by contrast, must be physically removed, a process that can cause tissue trauma or introduce infection (Kusumoto et al., 2019).

The bioresorbable pacemaker offers several key advantages over traditional temporary pacing systems. First, its minimally invasive implantation—potentially via injection or integration with other implants such as heart valve replacements—reduces procedural risks and recovery time (Lee et al., 2015). Second, the absence of external wires significantly lowers the risk of infection, which is a major concern with conventional temporary pacemakers, particularly in immunocompromised patients (Kusumoto et al., 2019). Third, the device’s ability to dissolve eliminates the need for a secondary removal procedure, reducing healthcare costs and improving patient outcomes (Yu et al., 2020).

The clinical significance of these differences is substantial. For example, in post-surgical cardiac care, where temporary pacing is often required for a short period, the bioresorbable pacemaker could prevent complications associated with lead extraction, such as venous damage or arrhythmias (Hwang et al., 2022). Additionally, pediatric patients, who are particularly vulnerable to complications from lead removal, could benefit from a device that naturally degrades without intervention. Children’s smaller anatomical structures and ongoing growth make traditional procedures challenging, with higher risks of vascular damage and cardiac tissue trauma, but a bioresorbable pacemaker eliminates these risks while accommodating the changes in a child’s developing cardiovascular system, potentially revolutionizing temporary cardiac care for pediatric populations.

Moreover, the development of bioresorbable electronics extends beyond cardiac pacing. Similar technologies could be applied to nerve regeneration, where temporary electrical stimulation could aid in repairing damaged nerves, or to bone healing, where dissolvable devices could provide targeted therapy without the need for removal (Yu et al., 2020). Furthermore, the integration of such devices with wearable sensors opens possibilities for closed-loop therapeutic systems that adjust treatment in response to real-time physiological data (Lee et al., 2015).

The medical device industry is likely to experience significant shifts as a result of these advancements. Manufacturers may increasingly focus on wireless, lead-free designs, while regulatory agencies could expedite approvals for bioresorbable technologies given their potential to reduce complications (Hwang et al., 2022). Additionally, the reduced need for follow-up surgeries and lower infection rates associated with these devices could lead to substantial cost savings for healthcare systems. While bioresorbable pacemakers eliminate many risks of traditional devices, researchers must still ensure long-term biocompatibility and refine optical power delivery to prevent overheating or inconsistent pacing. Although human trials show promise, clinical adoption may take between five to seven years pending safety optimization, regulatory approval, and scaled manufacturing.

The millimeter-scale bioresorbable pacemaker represents a transformative advancement in temporary cardiac pacing. By combining wireless optical control, minimally invasive implantation, and safe dissolution within the body, this device addresses many of the limitations associated with traditional temporary pacemakers. Its success in preclinical and clinical testing highlights its potential not only for cardiac care but also for a wide range of therapeutic applications. As research in bioresorbable medical devices continues to progress, these innovations are poised to redefine standards in patient care, offering safer, more efficient, and cost-effective solutions for temporary medical interventions.

References

Hwang, S. W., Tao, H., Kim, D. H., Cheng, H., Song, J. K., Rill, E., ... & Rogers, J. A. (2022). A physically transient form of silicon electronics. Science, 337(6102), 1640-1644. https://doi.org/10.1126/science.1226325

Kusumoto, F. M., Schoenfeld, M. H., Barrett, C., Edgerton, J. R., Ellenbogen, K. A., Gold, M. R., ... & Varosy, P. D. (2019). 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. Journal of the American College of Cardiology, 74(7), e51-e156. https://doi.org/10.1016/j.jacc.2018.10.044

Lee, C. H., Kim, H., Harburg, D. V., Park, G., Ma, Y., Pan, T., Kim, J. S., Lee, N. Y., Kim, B. H., Jang, K.-I., Kang, S.-K., Huang, Y., Kim, J., Lee, K.-M., Leal, C., & Rogers, J. A. (2015). Biological lipid membranes for on-demand, wireless drug delivery from thin, bioresorbable electronic implants. NPG Asia Materials, 7(11), e227–e227. https://doi.org/10.1038/am.2015.114

Yu, K. J., Kuzum, D., Hwang, S. W., Kim, B. H., Juul, H., Kim, N. H., ... & Litt, B. (2020). Bioresorbable silicon electronics for transient spatiotemporal mapping of electrical activity from the cerebral cortex. Nature Materials, 15(7), 782-791. https://doi.org/10.1038/nmat4624